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ABSTRACT 
Cross-sectional study of 36 children with acute lymphoblastic leukemia (ALL) or acute 
myeloid leukemia (AML). Intraoral examination and oral hygiene assessment were performed in 
all patients. Information was also obtained from interviews of patients’ mothers and a review of 
medical records. Results: The sample was largely composed of boys (58.3%), ages 5–9 years. The 
most commonly used chemotherapy regimen was the BFM-95 protocol. Most children (83.3%) 
had a record of some oral manifestation during treatment. On intraoral examination, 17 children 
(50%) were found to have at least one oral manifestation. The most frequent manifestation was also 
mucositis (26.5%), followed by gingival bleeding (23.4%). Lower maternal educational level was 
associated with increased frequency of mucositis, as were induction chemotherapy and maintenance 
chemotherapy after relapse. Conclusions: Oral abnormalities were common in children receiving 
chemotherapy and mucositis was the most prevalent manifestation. Oral lesions were associated 
with the induction phase of chemotherapy. Mucositis was not associated with oral health status.
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Manifestações bucais em pacientes pediátricos submetidos 
a quimioterapia para  leucemia
RESUMO
Estudo transversal de 36 crianças com leucemia linfoblástica aguda (LLA) ou leucemia 
mieloide aguda (LMA). Exame intraoral e avaliação de higiene bucal foram realizados em todos 
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os pacientes. A informação também foi obtida a partir de entrevistas com as mães dos pacientes 
e uma revisão dos registros médicos. Resultados: A amostra foi composta em grande parte 
dos meninos (58,3%), com idades entre 5-9 anos. O regime de quimioterapia mais comumente 
utilizado foi o protocolo BFM-95. A maioria das crianças (83,3%) teve um registro de alguma 
manifestação oral durante o tratamento. Ao exame intraoral, 17 crianças (50%) apresentaram ter 
pelo menos uma manifestação oral. A manifestação mais frequente foi mucosite (26,5%), seguido 
por sangramento gengival (23,4%). Baixa escolaridade materna foi associada com aumento da 
frequência de mucosite, assim como a quimioterapia de indução e quimioterapia de manutenção 
após recaída. Conclusões: Anormalidades orais são comuns em crianças que receberam 
quimioterapia e mucosite foi a manifestação mais prevalente. As lesões foram associados com 
a fase de indução da quimioterapia. Mucosite não foi associado com o estado de saúde oral.
Palavras-chave: Leucemia; Quimioterapia; Mucosite Bucal.
INTRODUCTION
Childhood cancer corresponds to a group of diseases characterized by the 
uncontrolled proliferation of atypical cells, which may occur anywhere in the body (1). 
The most common malignant neoplasms of childhood are the leukemias, central nervous 
system tumors, and the lymphomas (2). 
Among the leukemias, the most prevalent type is acute lymphoblastic leukemia 
(ALL), which is characterized by accumulation of immature lymphoid cells in the bone 
marrow (2,3) and accounts for roughly 80% of all cases of leukemia in childhood. The 
age of peak incidence is 2–5 years, and approximately 60% of cases occur before the 
age of 20. The survival rate of children with ALL is nearly 90% (4).  Acute myeloid 
leukemia (AML), which accounts for 15–20% of all leukemias in childhood, belongs to 
a heterogeneous group of hematopoietic malignancies of monoclonal origin, which result 
from the malignant transformation of a stem cell. These neoplasms can manifest with 
a myeloid, erythroid, or platelet precursor phenotype, or a combination thereof (5). The 
overall survival rate in children with AML is approximately 60–70% (6). 
Chemotherapy is the mainstay of treatment for all forms of leukemia. However, 
this treatment modality is necessarily associated with systemic or local adverse effects 
on healthy tissues. The oral manifestations associated whit chemotherapy are infl uenced 
by factors including the type, dosage, duration, and schedule of administration of 
chemotherapeutic agents; patient age; defi cient oral hygiene; and preexisting periodontal 
disease (7,8). These factors, in turn, infl uence the incidence of mucositis, decreased salivary 
fl ow (leading to xerostomia), pain (as a result of neurotoxicity), opportunistic infections 
(such as oral candidiasis), and gingival bleeding (9). 
Chemotherapy-associated oral mucositis occurs due to interference with epithelial 
cell turnover and induction of apoptosis (10,11). The indirect cytotoxic effects of the release 
of infl ammatory mediators, loss of protective salivary components, and treatment-induced 
neutropenia have been noted as contributors to the development of oral mucositis (12). 
Furthermore, chemotherapeutic agents such as fl uorouracil, methotrexate, daunorubicin, 
and cyclophosphamide, which are commonly used in ALL treatment protocols, are 
particularly toxic to the oral mucosa (13,14). 
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Dental follow-up should be considered during the various stages of leukemia 
treatment. Restoring oral health before antineoplastic treatment aims to prevent oral 
complications, whereas dental care during treatment seeks to manage these complications 
as they occur.
The objective of the present study was to evaluate oral manifestations in children 
receiving antineoplastic treatment for ALL or AML at a specialist pediatric cancer care 
center. We also sought to ascertain whether these complications are associated with oral 
hygiene status.
METHODS
Study design and setting
This cross-sectional study was conducted at the hematology/oncology clinic of 
Hospital da Criança Conceição (GHC), a children’s hospital located in Porto Alegre, 
state of Rio Grande do Sul, Brazil, over a 12-month period.
Participants and eligibility criteria
The eligible population comprised all children with a diagnosis of leukemia who 
were undergoing chemotherapy at the time of the study, regardless of phase, and whose 
legal guardian provided written informed consent for participation in the study.
During the recruitment period, 38 patients met the inclusion criteria. Of these, two 
children participated in the pilot study and were subsequently excluded from analysis. 
Therefore, the fi nal sample comprised 36 children with ALL and AML, aged 10 months 
to 15 years, of both sexes, who were being treated at GHC on an inpatient or outpatient 
basis.
Data collection
Data were collected from patient records, interviews with patients’ mothers or 
guardians, and from the intraoral examination.
Paper-based and digital records from the GHC electronic medical records system 
were analyzed to collect demographic variables (sex, age, skin color, place of origin) and 
clinical parameters (comorbidities; type, phase, and protocol of antineoplastic therapy; 
dental evaluation before or during treatment).
Interviews were conducted using a semi-structured questionnaire designed to 
collect information on the educational level of the child’s guardian and the child’s oral 
hygiene habits, as well as to confi rm clinical data obtained from medical records. The 
intraoral examination was performed in compliance with biosafety standards, under 
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artifi cial lighting, with children properly positioned (seated or in the supine position), and 
always in the presence of a legal guardian. Two patients were lost to follow-up during 
this stage: one was discharged from the hospital and the other refused examination. 
Thus, 34 examinations were performed. Intraoral examination consisted of assessment 
of all oral soft tissues, including the lips, tongue, fl oor of mouth, cheek mucosa, palate, 
ridges/gums, buccal vestibule, and oropharynx. When present, mucositis was graded by 
severity (I to IV) (15). Any opportunistic infections identifi ed were classifi ed by etiology 
as fungal, viral, or bacterial (16,17). Patients were also examined for gingival hyperplasia 
and bleeding, mucosal pallor, and dry mucous membranes indicating decreased salivary 
fl ow. The extraoral examination was limited to evaluation of the presence of regional 
lymphadenopathy.
Oral hygiene status was evaluated by means of the Simplifi ed Oral Hygiene 
Index (OHI-S), modifi ed for the deciduous dentition when necessary (18). Total 
OHI-S scores were classifi ed as dental plaque absent (score = 0) or present (score > 1) 
and, subsequently, re-categorized as indicative of satisfactory or unsatisfactory oral 
hygiene, respectively (19). 
Data analysis
Data were analyzed in SPSS Version 20.0. Results were expressed as absolute 
and relative frequencies. The chi-square and Fisher’s exact tests were used to evaluate 
associations of mucositis and oral hygiene with demographic and clinical variables. 
Signifi cance was accepted at P < 5%.
Ethics
The study was approved by the Research Ethics Committee of Grupo Hospitalar 
Conceição – GHC (CEP/GHC: 116/08, FR: 202971). All procedures performed in 
studies involving human participants were in accordance with the ethical standards of the 
institutional and/or national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
RESULTS
Of the 36 patients included in the study, 91.7% had a diagnosis of ALL with no 
associated conditions or comorbidities (83.3%). The sample was largely composed of 
boys (58.3%), ages 5–9 years (52.8%), from other municipalities (72.2%) (Table 1).
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TABLE 1 – Distribution of demographic and clinical variables in children receiving antineoplastic therapy for 
leukemia (n = 36).
Variable n %
Diagnosis
ALL 33 91.7
AML 03 8.3
Sex
Male 21 58.3
Female 15 41.7
Age (years)
≤ 04 09 25.0
05 to 09 19 52.8
10 to 15 08 22.2
Skin color
White 35 97.2
Non-white 01 2.8
Place of origin
Porto Alegre 10 27.8
Other municipalities 26 72.2
Comorbidities
None 30 83.3
Hemophilia 01 2.8
Down syndrome 03 8.3
Obesity 01 2.8
Ewing sarcoma 01 2.8
Treatment modality
Chemotherapy 31 86.1
Chemotherapy and radiotherapy 05 13.9
Chemotherapy phase
Induction of remission 08 22.2
Maintenance of remission 18 50.0
Maintenance after relapse 09 25.0
Treatment completed 01 2.8
Chemotherapy protocol
BFM 95 24 66.7
POG 9061 04 11.1
BFM-93 03 8.3
BFM-95 – relapse 03 8.3
Hyper-CVAD 01 2.8
CCG 1941 01 2.8
Dental evaluation
Yes 25 69.4
No 10 27.8
N/A 01 2.8
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BFM, Berlin-Frankfurt-Munich; POG, 
Pediatric Oncology Group; Hyper-CVAD, high-dose cyclophosphamide, vincristine, Adriamycin, dexamethasone; 
CCG, Children’s Cancer Group; N/A, not available.
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Regarding the treatment modalities employed, 31 children (86.1%) received 
chemotherapy alone, and only fi ve (13.9%) received combined chemotherapy and 
radiation therapy. However, at the time of examination for the present study, all participants 
were undergoing chemotherapy exclusively. Regarding the phase of chemotherapy, 50% 
of children were in maintenance of remission, and the most commonly used chemotherapy 
regimen was the BFM 95 (Berlin-Frankfurt-Munich) protocol (66.7%). Twenty-fi ve 
children (69.4%) had undergone dental evaluation by a hospital-affi liated dentist before 
or during treatment (Table 1).
Data obtained from charts showed that 30 children (83.3%) had a record of some 
oral manifestation, isolated or in combination, during treatment. The most prevalent 
manifestations were mucositis (73.3%), gingival bleeding (30%), herpesviral infections 
(26.7%), candidiasis (23.3%), and parotitis (10%).
On intraoral examination performed for the present study, 17 children (50%) were 
found to have at least one oral manifestation. The most frequent manifestation was 
mucositis (26.5%), followed by gingival bleeding (23.4%) (Table 2). No abnormalities 
were found on extraoral examination.
Most cases of mucositis identifi ed were classifi ed as grade I or II. There were no 
cases of grade III mucositis, and only one case of grade IV mucositis. The most commonly 
affected sites were the lip and tongue mucosa, alone or in combination with other areas 
(Table 3).
TABLE 2 – Distribution of oral manifestations at the time of examination in children receiving chemotherapy (n = 34).
Oral manifestations n %
Mucositis 09 26.5
Gingival bleeding 08 23.4
Pale mucous membranes 05 14.7
Candidiasis 03 8.8
Dry mucous membranes 02 5.8
TABLE 3 – Distribution of the severity and sites of mucositis in children receiving chemotherapy (n = 9).
Mucositis n %
Classifi cation
Grade I 04 44.4
Grade II 04 44.4
Grade III 00 00
Grade IV 01 11.2
Site
Lips 02 22.2
Tongue 02 22.2
Cheek mucosa 01 11.2
Buccal vestibule 01 11.2
More than one site 03 33.3
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Table 4 shows the relationship between presence of mucositis and demographic 
and clinical variables. A signifi cant association was found with maternal educational 
attainment (P = 0.032); children whose mothers had a lower educational level presented 
with a greater frequency of this complication. Phase of chemotherapy was also associated 
with mucositis (P = 0.024): the induction of remission and maintenance after relapse phases 
were those most often related. The highest percentage of children without mucositis was 
found among those receiving chemotherapy for maintenance of remission (64.0%).
TABLE 4 – Associations between presence of mucositis and demographic and clinical variables in children 
receiving chemotherapy (n = 34).
Variable Mucositis n (%) No mucositis n (%) P
Maternal educational level 0.032*
Some primary education 02 (22.2%) 13 (52.0%)
Completed primary education 04 (44.4%) 01 (4.0%)
Some secondary education 0 (0.0%) 01 (4.0%)
Completed secondary education 03 (33.3%) 04 (16.0%)
Higher education 0 (0.0%) 03 (12.0%)
N/A 0 (0.0%) 03 (12.0%)
Age (years) 0.235*
≤ 04 02 (22.2%) 06 (25.0%)
05 to 09 03 (33.3%) 04 (58.3%)
10 to 15 04 (44.4%) 04 (16.7%)
Oral hygiene 0.162**
Satisfactory 05 (55.6%) 20 (80.0%)
Unsatisfactory 04 (44.4%) 05 (20.0%)
Treatment phase 0.024**
Induction of remission 04 (44.4%) 04 (16.0%)
Maintenance of remission 01 (11.1%) 16 (64.0%)
Maintenance after relapse 04 (44.4%) 05 (20.0%)
N/A, not available.
*Chi-square test; **Fisher’s exact test.
Oral hygiene status was considered satisfactory in 25 cases (73.5%), and was not 
associated with maternal educational level (P = 0.221) or with dental assessment by a 
hospital-affi liated practitioner (P = 0.124) (Table 5).
TABLE 5 – Association of oral hygiene status with maternal educational level and dental evaluation before and 
during chemotherapeutic treatment (n = 34).
Variable Satisfactory OH
n (%)
Unsatisfactory OH
n (%) P
Maternal educational level 0.221*
Some primary education 9 (36.0%) 6 (66.7%)
Completed primary education 4 (16.0%) 1 (11.1%)
Some secondary education 0 (0.0%) 1 (11.1%)
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Variable Satisfactory OH
n (%)
Unsatisfactory OH
n (%) P
Completed secondary education 6 (24.0%) 1 (11.1%)
Higher education 3 (12.0%) 0 (0.0%)
N/A 3 (12.0%) 0 (0.0%)
Dental evaluation 0.124*
Yes 19 (76.0%) 4 (44.4%)
No 5 (20.0%) 5 (55.6%)
N/A 1 (4.0%) 0 (0.0%)
OH, oral hygiene; N/A, not available.
*Chi-square test.
DISCUSSION
Over 80% of children participating in this study had a record of oral manifestations 
during chemotherapeutic treatment. At the time of intraoral examination, 50% of children 
had such complications, with a higher rate found among those under the age of 9. The 
younger the patient, the greater the likelihood of the oral mucosa being affected by 
chemotherapy; up to 90% of children under 12 experience oral complications (7). 
At the time of examination, all children were in chemotherapy, and mucositis was 
the most prevalent oral manifestation, regardless of chemotherapy phase or regimen. Oral 
mucositis is a complication generally associated with chemotherapy dosages or protocols 
that cause leukopenia secondary to neutropenia (14,20). However, we were unable to test 
for an association of mucositis with neutropenia, (17) as the patients included were at 
distinct treatment phases.
Investigation of the association between phase of chemotherapeutic treatment and 
presence of mucositis revealed a signifi cant association (P = 0.024) with the remission 
induction and maintenance with recurrence phases, which were related to the highest 
frequencies of mucositis at the time of intraoral examination. This association may be 
attributable to the greater number of chemotherapy agents used in combination during 
these phases, such as vincristine, daunorubicin, and methotrexate, which have been 
implicated as the main causative agents of oral mucositis (17). Of the patients analyzed, 
66.7% were receiving the BFM 95 (Berlin-Frankfurt-Munich) protocol. This regimen 
involves drugs such as methotrexate, which is commonly associated with development of 
mucositis. On the other hand, the maintenance of remission phase of chemotherapy, which 
was the most frequent treatment stage at the time of examination, was also associated 
with the highest rate of children without mucositis (64.0%). This is consistent with the 
fi ndings of Ribas and Araújo (21). Episodes of mucositis most frequently affected the lip 
mucosa and lateral aspect of the tongue, which may be explained by the fact that these 
are areas of nonkeratinized mucosa (22). Most lesions were classifi ed as grade I or II. 
The frequency and severity of chemotherapy-induced mucositis may be related to risk 
factors inherent to each patient, such as type of leukemia, age, and oral hygiene status 
(14,23,24). 
Stomatos, Vol. 22, Nº 43, Jul./Dec. 201628
Investigation of patient-related factors revealed an association of mucositis with 
maternal educational level (P = 0.032); children whose mothers had a lower degree 
of educational attainment exhibited higher rates of mucositis. However, it should be 
taken into consideration that all 18 children (50%) who exhibited satisfactory oral 
hygiene were in the maintenance phase of chemotherapy, which involves a protocol 
of fewer chemotherapeutic agents and, consequently, is associated with lower risk of 
oral manifestations.
Furthermore, considering that low household income (25) and maternal educational 
level may infl uence the oral hygiene status of children, (26) the mothers of 66.7% of the 
children who exhibited unsatisfactory oral hygiene had fewer than 8 years of formal 
education. However, no signifi cant association was found (P = 0.221). The emotional status 
of the child and their family members regarding the disease and the treatment process 
itself should also be taken into account, as concerns with oral hygiene are relegated to 
the background in such situations.
On the other hand, the lack of awareness of the fact that oral hygiene habits play 
a relevant role in preserving or improving the overall health of the child reinforces 
the importance of including dentists in multidisciplinary oncology teams. Guidance, 
encouragement, and follow-up of oral health in these patients is paramount to preventing 
or mitigating the oral complications of antineoplastic therapy.
According to Hespanhol et al., (27) all patients who will receive chemotherapy 
must undergo prior dental examination to identify and treat potential foci of infection 
before development of granulocytopenia, and periodic monitoring should be performed 
throughout the course of treatment.
Gingival bleeding, observed in approximately 25% of cases in our sample, was also 
reported in previous studies (28). This condition may be associated with thrombocytopenia 
secondary to myelosuppressive chemotherapy. Although the present study did not 
investigate this association, it is known that patients with systemic involvement who are 
receiving chemotherapy have defi ciencies in coagulation and their gums may bleed at the 
lightest touch; this bleeding may be aggravated by unsatisfactory oral hygiene.
Other oral manifestations observed with a lower frequency in the present study 
included oral mucosal pallor, dry mucous membranes, and candidiasis. A previous study 
by Mendonça et al. (29)  also reported a lower frequency of these manifestations, which 
are believed to be associated with decreased salivary fl ow, neutropenia, and severity of 
mucositis. The mucosal dryness caused by chemotherapy usually represents a transient 
alteration in salivary gland function, and resolves shortly after conclusion of treatment 
or dose reduction (28). This is consistent with the fi ndings of the present study, in which 
only 8.8% of patients had candidiasis and 5.8% had dry mucous membranes at the time 
of examination; half of the sample was in the maintenance phase of chemotherapy, which 
involves a smaller amount of chemotherapeutic agents.
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CONCLUSION
The ALL treatment protocols used at specialized cancer centers are often adapted. 
This practice should be taken into account when investigating oral conditions in their 
patients, who may present with oral manifestations of varying types and severities. 
Knowledge of the chemotherapy regimens, phases, and protocols used in the treatment of 
childhood leukemia is important for identifying associated oral manifestations, particularly 
mucositis. Constant evaluation and monitoring of oral hygiene and oral health is of the 
utmost importance in patients undergoing treatment for leukemia. Another important 
intervention is to educate, guide, and encourage patients, their family members, and 
the nursing team to maintain a satisfactory standard of oral hygiene, so as to prevent or 
minimize the risk of oral manifestations of antineoplastic treatment and improve patient 
quality of life.
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